Cargando…
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk
Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (GWAS) data in the public domain to investigat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835528/ https://www.ncbi.nlm.nih.gov/pubmed/26946290 http://dx.doi.org/10.1007/s00439-016-1647-9 |
_version_ | 1782427620453908480 |
---|---|
author | Tragante, Vinicius Asselbergs, Folkert W. Swerdlow, Daniel I. Palmer, Tom M. Moore, Jason H. de Bakker, Paul I. W. Keating, Brendan J. Holmes, Michael V. |
author_facet | Tragante, Vinicius Asselbergs, Folkert W. Swerdlow, Daniel I. Palmer, Tom M. Moore, Jason H. de Bakker, Paul I. W. Keating, Brendan J. Holmes, Michael V. |
author_sort | Tragante, Vinicius |
collection | PubMed |
description | Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (GWAS) data in the public domain to investigate the relationship of LDL-C and diabetes and identify loci encoding potential drug targets for LDL-cholesterol modification without causing dysglycemia. We obtained summary-level GWAS data for LDL-C from GLGC, glycemic traits from MAGIC, diabetes from DIAGRAM and CAD from CARDIoGRAMplusC4D consortia. Mendelian randomization analyses identified a one standard deviation (SD) increase in LDL-C caused an increased risk of CAD (odds ratio [OR] 1.63 (95 % confidence interval [CI] 1.55, 1.71), which was not influenced by removing SNPs associated with diabetes. LDL-C/CAD-associated SNPs showed consistent effect directions (binomial P = 6.85 × 10(−5)). Conversely, a 1-SD increase in LDL-C was causally protective of diabetes (OR 0.86; 95 % CI 0.81, 0.91), however LDL-cholesterol/diabetes-associated SNPs did not show consistent effect directions (binomial P = 0.15). HMGCR, our positive control, associated with LDL-C, CAD and a glycemic composite (derived from GWAS meta-analysis of four glycemic traits and diabetes). In contrast, PCSK9, APOB, LPA, CETP, PLG, NPC1L1 and ALDH2 were identified as “druggable” loci that alter LDL-C and risk of CAD without displaying associations with dysglycemia. In conclusion, LDL-C increases the risk of CAD and the relationship is independent of any association of LDL-C with diabetes. Loci that encode targets of emerging LDL-C lowering drugs do not associate with dysglycemia, and this provides provisional evidence that new LDL-C lowering drugs (such as PCSK9 inhibitors) may not influence risk of diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00439-016-1647-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4835528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-48355282016-05-04 Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk Tragante, Vinicius Asselbergs, Folkert W. Swerdlow, Daniel I. Palmer, Tom M. Moore, Jason H. de Bakker, Paul I. W. Keating, Brendan J. Holmes, Michael V. Hum Genet Original Investigation Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (GWAS) data in the public domain to investigate the relationship of LDL-C and diabetes and identify loci encoding potential drug targets for LDL-cholesterol modification without causing dysglycemia. We obtained summary-level GWAS data for LDL-C from GLGC, glycemic traits from MAGIC, diabetes from DIAGRAM and CAD from CARDIoGRAMplusC4D consortia. Mendelian randomization analyses identified a one standard deviation (SD) increase in LDL-C caused an increased risk of CAD (odds ratio [OR] 1.63 (95 % confidence interval [CI] 1.55, 1.71), which was not influenced by removing SNPs associated with diabetes. LDL-C/CAD-associated SNPs showed consistent effect directions (binomial P = 6.85 × 10(−5)). Conversely, a 1-SD increase in LDL-C was causally protective of diabetes (OR 0.86; 95 % CI 0.81, 0.91), however LDL-cholesterol/diabetes-associated SNPs did not show consistent effect directions (binomial P = 0.15). HMGCR, our positive control, associated with LDL-C, CAD and a glycemic composite (derived from GWAS meta-analysis of four glycemic traits and diabetes). In contrast, PCSK9, APOB, LPA, CETP, PLG, NPC1L1 and ALDH2 were identified as “druggable” loci that alter LDL-C and risk of CAD without displaying associations with dysglycemia. In conclusion, LDL-C increases the risk of CAD and the relationship is independent of any association of LDL-C with diabetes. Loci that encode targets of emerging LDL-C lowering drugs do not associate with dysglycemia, and this provides provisional evidence that new LDL-C lowering drugs (such as PCSK9 inhibitors) may not influence risk of diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00439-016-1647-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-03-05 2016 /pmc/articles/PMC4835528/ /pubmed/26946290 http://dx.doi.org/10.1007/s00439-016-1647-9 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Investigation Tragante, Vinicius Asselbergs, Folkert W. Swerdlow, Daniel I. Palmer, Tom M. Moore, Jason H. de Bakker, Paul I. W. Keating, Brendan J. Holmes, Michael V. Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
title | Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
title_full | Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
title_fullStr | Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
title_full_unstemmed | Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
title_short | Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
title_sort | harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835528/ https://www.ncbi.nlm.nih.gov/pubmed/26946290 http://dx.doi.org/10.1007/s00439-016-1647-9 |
work_keys_str_mv | AT tragantevinicius harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT asselbergsfolkertw harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT swerdlowdanieli harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT palmertomm harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT moorejasonh harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT debakkerpauliw harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT keatingbrendanj harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk AT holmesmichaelv harnessingpubliclyavailablegeneticdatatoprioritizelipidmodifyingtherapeutictargetsforpreventionofcoronaryheartdiseasebasedondysglycemicrisk |